|
UA68327C2
(en)
*
|
1995-07-04 |
2004-08-16 |
Gsf Forschungszentrum Fur Unwe |
A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
|
|
US7118754B1
(en)
*
|
1996-07-30 |
2006-10-10 |
Transgene S.A. |
Pharmaceutical composition for treating papillomavirus tumors and infection
|
|
MY150893A
(en)
*
|
1996-09-24 |
2014-03-14 |
Bavarian Nordic As |
Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
MY119381A
(en)
*
|
1996-12-24 |
2005-05-31 |
Gsf Forschungszentrum Umwelt |
Recombinant mva virus, and the use thereof
|
|
US6969609B1
(en)
*
|
1998-12-09 |
2005-11-29 |
The United States Of America As Represented By The Department Of Health And Human Serivces |
Recombinant vector expressing multiple costimulatory molecules and uses thereof
|
|
FR2784997A1
(fr)
*
|
1998-10-22 |
2000-04-28 |
Transgene Sa |
Materiel biologique pour la preparation de compositions pharmaceutiques destinees au traitement de mammiferes
|
|
US20040265324A1
(en)
*
|
1999-03-23 |
2004-12-30 |
Cardosa Mary Jane |
Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
|
|
US6682742B1
(en)
|
1999-05-28 |
2004-01-27 |
Gsf Forschungszentrum Fur Unwelt Und Gesundheit Gmbh |
Vector for integration of heterologous sequences into poxviral genomes
|
|
US20150231227A1
(en)
*
|
2000-03-02 |
2015-08-20 |
Emory University |
Compositions and methods for generating an immune response
|
|
NZ521270A
(en)
|
2000-03-14 |
2003-06-30 |
Bavarian Nordic As |
Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line
|
|
RU2217162C2
(ru)
*
|
2000-04-10 |
2003-11-27 |
Государственный научный центр вирусологии и биотехнологии "Вектор" |
Вакцина против вирусных инфекций
|
|
DE10042598A1
(de)
*
|
2000-08-30 |
2002-03-28 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression des HER-2/Neu-GENS
|
|
AU2002211654A1
(en)
*
|
2000-10-10 |
2002-04-22 |
Genstar Therapeutics |
Minimal adenoviral vector and recombinant vaccines based thereon
|
|
US7445924B2
(en)
|
2000-11-23 |
2008-11-04 |
Bavarian Nordic A/S |
Modified Vaccinia Ankara virus variant and cultivation method
|
|
DE20122302U1
(de)
|
2000-11-23 |
2005-02-24 |
Bavarian Nordic A/S |
Variante des Modifizierten Vaccinia-Ankara-Virus
|
|
US7628980B2
(en)
|
2000-11-23 |
2009-12-08 |
Bavarian Nordic A/S |
Modified vaccinia virus ankara for the vaccination of neonates
|
|
US7740863B2
(en)
|
2001-04-06 |
2010-06-22 |
Merial |
Recombinant vaccine against West Nile Virus
|
|
DE10143490C2
(de)
*
|
2001-09-05 |
2003-12-11 |
Gsf Forschungszentrum Umwelt |
Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen
|
|
DE10144664B4
(de)
*
|
2001-09-11 |
2005-06-09 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vacciniavirus MVA-E3L-Knock-Out-Mutanten und Verwendung hiervon
|
|
AU2002356690B2
(en)
|
2001-12-04 |
2008-07-24 |
Bavarian Nordic A/S |
Flavivirus NS1 subunit vaccine
|
|
ATE302268T1
(de)
*
|
2001-12-20 |
2005-09-15 |
Bavarian Nordic As |
Methode zur gewinnung und reinigung von poxviren aus infizierten zellen
|
|
JP4801880B2
(ja)
*
|
2002-04-19 |
2011-10-26 |
バヴァリアン・ノルディック・アクティーゼルスカブ |
新生仔予防接種用変異ワクシニアウイルスアンカラ
|
|
MXPA04011034A
(es)
*
|
2002-05-16 |
2005-02-14 |
Bavarian Nordic As |
Expresion de los genes en el virus de la vacuna de ankara modificada, usando el promotor ati de viruela.
|
|
US7501127B2
(en)
|
2002-05-16 |
2009-03-10 |
Bavarian Nordic A/S |
Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
|
|
EP2253709B1
(en)
|
2002-05-16 |
2018-04-11 |
Bavarian Nordic A/S |
Recombinant poxvirus expressing homologous genes inserted into the poxviral genome
|
|
UA85543C2
(ru)
|
2002-09-05 |
2009-02-10 |
Бавариан Нордик А/С |
Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных
|
|
DE10249390A1
(de)
*
|
2002-10-23 |
2004-05-13 |
Ruprecht-Karls-Universität Heidelberg |
Rekombinante MVA-Stämme als potentielle Impfstoffe gegen P.falciparum-Malaria
|
|
DE60314541T2
(de)
*
|
2002-11-25 |
2008-02-28 |
Bavarian Nordic A/S |
Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
|
|
CN1723285B
(zh)
*
|
2003-02-18 |
2013-01-02 |
德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 |
重组的mva及其产生方法
|
|
WO2005048957A2
(en)
*
|
2003-02-20 |
2005-06-02 |
Therion Biologics Corporation |
Novel insertion sites in pox vectors
|
|
EP1606411B1
(en)
|
2003-03-27 |
2008-12-10 |
Ottawa Health Research Institute |
Mutant vesicular stomatitis viruses and use thereof
|
|
US7731974B2
(en)
*
|
2003-03-27 |
2010-06-08 |
Ottawa Hospital Research Institute |
Mutant vesicular stomatitis viruses and uses thereof
|
|
WO2004093905A1
(en)
*
|
2003-04-16 |
2004-11-04 |
City Of Hope |
Human cytomegalovirus antigens expressed in mva and methods of use
|
|
GB2402391A
(en)
*
|
2003-06-04 |
2004-12-08 |
Oxxon Pharmaccines Ltd |
Fowlpox recombinant genome
|
|
DE602004031681D1
(de)
|
2003-07-21 |
2011-04-14 |
Transgene Sa |
Multifunktionelle Cytokine
|
|
WO2005017208A1
(en)
*
|
2003-07-31 |
2005-02-24 |
George Mason Intellectual Properties, Inc. |
Compositions and methods for treating or preventing hiv infection
|
|
EP1518932A1
(en)
*
|
2003-09-29 |
2005-03-30 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Modified vaccinia virus Ankara (MVA) mutant and use thereof
|
|
DE602004009743T2
(de)
*
|
2003-11-24 |
2008-08-28 |
Bavarian Nordic A/S |
Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara
|
|
EP1710300A4
(en)
|
2003-12-05 |
2007-10-24 |
Hokkaido Tech Licensing Office |
HIGHLY SAFE POX VACCINE VIRUS AND VACCINIA VIRUS VECTOR
|
|
EP1683870A1
(en)
*
|
2005-01-24 |
2006-07-26 |
GSF-Forschungszentrum für Umwelt und Gesundheit GmbH |
Vaccines based on the use of MVA
|
|
US20090269365A1
(en)
*
|
2005-04-20 |
2009-10-29 |
University Of Washington |
Immunogenic vaccinia peptides and methods of using same
|
|
CA2670804A1
(en)
*
|
2006-05-19 |
2007-11-29 |
Sanofi Pasteur Inc. |
Immunological composition
|
|
KR101082296B1
(ko)
*
|
2006-06-20 |
2011-11-09 |
트랜스진 에스.에이. |
폭스바이러스 및 폭스바이러스 조성물 제조 방법
|
|
US7972605B2
(en)
*
|
2006-09-08 |
2011-07-05 |
Duke University |
Modified vaccinia ankara virus vaccine
|
|
CN105769931B
(zh)
|
2006-09-15 |
2021-04-27 |
渥太华医院研究机构 |
溶瘤弹状病毒
|
|
EP2073837B1
(en)
|
2006-10-06 |
2014-06-25 |
Bavarian Nordic Inc. |
Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer
|
|
US20080241139A1
(en)
*
|
2006-10-31 |
2008-10-02 |
Regents Of The University Of Colorado |
Adjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
|
|
US20090175838A1
(en)
*
|
2007-01-26 |
2009-07-09 |
Newell Rogers M Karen |
Methods of modulating immune function
|
|
EP2208737B1
(en)
|
2007-05-03 |
2017-07-05 |
Lysomab GmbH |
Complement factor H-derived short consensus repeat-antibody constructs
|
|
US8003364B2
(en)
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia viruses using hydrophobic interaction chromatography
|
|
NZ578960A
(en)
*
|
2007-05-14 |
2012-11-30 |
Bavarian Nordic As |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
US8003363B2
(en)
*
|
2007-05-14 |
2011-08-23 |
Bavarian Nordic A/S |
Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
|
|
US20100285050A1
(en)
*
|
2007-10-05 |
2010-11-11 |
Isis Innovation Limited |
Compositions and Methods
|
|
BRPI0800485B8
(pt)
*
|
2008-01-17 |
2021-05-25 |
Univ Minas Gerais |
vetores virais recombinantes, composição vacinal para leishmaniose e método de vacinação para leishmaniose
|
|
JP2011511640A
(ja)
|
2008-02-12 |
2011-04-14 |
サノフィ パストゥール リミテッド |
ポックス・ウイルスの精製方法
|
|
US20110052627A1
(en)
*
|
2008-06-20 |
2011-03-03 |
Paul Chaplin |
Recombinant modified vaccinia virus measles vaccine
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
CA2760315C
(en)
|
2009-04-30 |
2019-05-28 |
Centre Hospitalier Universitaire Vaudois Lausanne (Chuv) |
Modified immunization vectors
|
|
NZ598000A
(en)
*
|
2009-08-07 |
2013-10-25 |
Transgene Sa |
Composition for treating hbv infection
|
|
WO2011063359A1
(en)
*
|
2009-11-20 |
2011-05-26 |
Inviragen, Inc. |
Compositions, methods and uses for poxvirus elements in vaccine constructs
|
|
US9005632B2
(en)
|
2009-11-20 |
2015-04-14 |
Takeda Vaccines, Inc. |
Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains
|
|
CA2793959C
(en)
|
2010-03-25 |
2019-06-04 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
GB201006405D0
(en)
*
|
2010-04-16 |
2010-06-02 |
Isis Innovation |
Poxvirus expression system
|
|
US20110262965A1
(en)
*
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
|
EP2668201A2
(en)
|
2011-01-28 |
2013-12-04 |
Sanofi Pasteur SA |
Immunological compositions comprising hiv gp41 polypeptide derivatives
|
|
WO2012151272A2
(en)
|
2011-05-02 |
2012-11-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
PT2691530T
(pt)
|
2011-06-10 |
2018-05-10 |
Univ Oregon Health & Science |
Glicoproteínas e vectores recombinantes cmv
|
|
JP6243333B2
(ja)
|
2011-08-05 |
2017-12-06 |
シラジェン バイオセラピューティクス インコーポレイテッド |
ワクシニアウィルスの生成のための方法および組成物
|
|
EP2568289A3
(en)
|
2011-09-12 |
2013-04-03 |
International AIDS Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
|
CA2849652C
(en)
*
|
2011-09-26 |
2017-11-21 |
Theravectys |
Use of non-subtype b gag proteins for lentiviral packaging
|
|
EP2586461A1
(en)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Viral particles derived from an enveloped virus
|
|
EP2788021B1
(en)
|
2011-12-09 |
2017-01-18 |
Bavarian Nordic A/S |
Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
|
|
EP2620446A1
(en)
|
2012-01-27 |
2013-07-31 |
Laboratorios Del Dr. Esteve, S.A. |
Immunogens for HIV vaccination
|
|
ES2631608T3
(es)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Variante de la glicoproteína Env del VIH-1
|
|
US10357555B2
(en)
|
2012-07-10 |
2019-07-23 |
Transgene Sa |
Mycobacterial antigen vaccine
|
|
WO2014009433A1
(en)
|
2012-07-10 |
2014-01-16 |
Transgene Sa |
Mycobacterium resuscitation promoting factor for use as adjuvant
|
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
|
EP2912069B1
(en)
|
2012-10-23 |
2019-07-31 |
Emory University |
Gm-csf and il-4 conjugates, compositions, and methods related thereto
|
|
US20140286981A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Wisconsin Alumni Research Foundation |
Broadly reactive mosaic peptide for influenza vaccine
|
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
|
RU2695462C2
(ru)
|
2014-01-09 |
2019-07-23 |
Трансген Са |
Гибридизация гетероолигомерных микобактериальных антигенов
|
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
CA2961024A1
(en)
|
2014-09-26 |
2016-03-31 |
Beth Israel Deaconess Medical Center, Inc. |
Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
|
|
EP3244919A4
(en)
|
2015-01-12 |
2018-06-27 |
Geovax, Inc. |
Compositions and methods for generating an immune response to a hemorrhagic fever virus
|
|
WO2016128542A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
US9931394B2
(en)
|
2015-03-23 |
2018-04-03 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
CA3008542C
(en)
|
2015-12-15 |
2020-06-02 |
Janssen Vaccines & Prevention B.V. |
Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
|
|
PL3402802T3
(pl)
|
2016-01-08 |
2023-06-05 |
Geovax, Inc. |
Kompozycje i sposoby generowania odpowiedzi immunologicznej względem antygenu powiązanego z guzem nowotworowym
|
|
WO2017136419A1
(en)
|
2016-02-03 |
2017-08-10 |
Geovax Inc. |
Compositions and methods for generating an immune response to a flavivirus
|
|
IL261321B2
(en)
*
|
2016-02-25 |
2023-12-01 |
Memorial Sloan Kettering Cancer Center |
Recombinant MVA or MVADELE3L expressing human FLT3L and their use as immunotherapeutic agents against solid tumors
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
JP6595132B2
(ja)
|
2016-06-16 |
2019-10-23 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
Ｈｉｖワクチン製剤
|
|
CN110494159A
(zh)
|
2016-09-02 |
2019-11-22 |
扬森疫苗与预防公司 |
在接受抗逆转录病毒治疗的对象中诱导针对人类免疫缺陷病毒感染的免疫应答的方法
|
|
SG10202001956UA
(en)
|
2016-09-15 |
2020-04-29 |
Janssen Vaccines & Prevention Bv |
Trimer stabilizing hiv envelope protein mutations
|
|
US20190328869A1
(en)
|
2016-10-10 |
2019-10-31 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
EP3638302B1
(en)
|
2017-06-15 |
2024-03-13 |
Janssen Vaccines & Prevention B.V. |
Poxvirus vectors encoding hiv antigens, and methods of use thereof
|
|
KR102684237B1
(ko)
|
2017-06-21 |
2024-07-11 |
트랜스진 |
개인 맞춤형 백신
|
|
MY200554A
(en)
|
2017-07-19 |
2024-01-03 |
Janssen Vaccines & Prevention Bv |
Trimer stabilizing hiv envelope protein mutations
|
|
WO2019018724A1
(en)
|
2017-07-21 |
2019-01-24 |
Janssen Vaccines & Prevention B.V. |
METHODS FOR SAFE INDUCTION OF MULTICLADED CROSS-IMMUNITY AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN BEINGS
|
|
WO2019055888A1
(en)
|
2017-09-18 |
2019-03-21 |
Janssen Vaccines & Prevention B.V. |
METHODS OF INDUCING AN IMMUNE RESPONSE AGAINST HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN SUBJECTS UNDER ANTIRETROVIRAL TREATMENT
|
|
US11311612B2
(en)
|
2017-09-19 |
2022-04-26 |
Geovax, Inc. |
Compositions and methods for generating an immune response to treat or prevent malaria
|
|
JP7551496B2
(ja)
|
2017-10-31 |
2024-09-17 |
カリヴィル イムノセラピューティクス， インコーポレイテッド |
全身送達のためのプラットフォーム腫瘍溶解性ベクター
|
|
CN111315407B
(zh)
|
2018-09-11 |
2023-05-02 |
上海市公共卫生临床中心 |
一种广谱抗流感疫苗免疫原及其应用
|
|
WO2020237052A1
(en)
|
2019-05-22 |
2020-11-26 |
Janssen Vaccines & Prevention B.V. |
Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
|
|
WO2021076998A1
(en)
*
|
2019-10-16 |
2021-04-22 |
KaliVir Immunotherapeutics LLC |
Producer viruses for generation of retroviruses in situ
|
|
EP4058058A1
(en)
|
2019-11-14 |
2022-09-21 |
Aelix Therapeutics S.L. |
Dosage regimens for vaccines
|
|
EP3842065A1
(en)
|
2019-12-23 |
2021-06-30 |
Transgene |
Process for designing a recombinant poxvirus for a therapeutic vaccine
|
|
WO2021260065A1
(en)
|
2020-06-24 |
2021-12-30 |
Consejo Superior De Investigaciones Científicas (Csic) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
EP3928789A1
(en)
|
2020-06-24 |
2021-12-29 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vaccine against covid-19 expressing sars-cov-2 antigens
|
|
WO2022109133A1
(en)
|
2020-11-19 |
2022-05-27 |
Kalivir Immunotherapeutics, Inc. |
Oncolytic immunotherapy by tumor micro-environment remodeling
|
|
WO2022232375A1
(en)
|
2021-04-30 |
2022-11-03 |
Kalivir Immunotherapeutics, Inc. |
Oncolytic viruses for modified mhc expression
|
|
EP4358999A1
(en)
|
2021-06-23 |
2024-05-01 |
Consejo Superior De Investigaciones Científicas |
Mva-based vaccine expressing a prefusion-stabilized sars-cov-2 s protein
|
|
EP4108257A1
(en)
|
2021-06-23 |
2022-12-28 |
Consejo Superior De Investigaciones Científicas |
Mva-based vaccine against covid-19 expressing a prefusion-stabilized sars-cov-2 s protein
|
|
WO2023077147A2
(en)
|
2021-11-01 |
2023-05-04 |
Pellis Therapeutics, Inc. |
T-cell vaccines for patients with reduced humoral immunity
|
|
WO2023213763A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
US20230364227A1
(en)
|
2022-05-12 |
2023-11-16 |
Pellis Therapeutics, Inc. |
Poxvirus adjuvant for t-cell vaccination
|
|
EP4316514A1
(en)
|
2022-08-03 |
2024-02-07 |
Consejo Superior de Investigaciones Científicas (CSIC) |
Mva-based vectors and their use as vaccine against sars-cov-2
|
|
WO2024193905A1
(en)
|
2023-03-17 |
2024-09-26 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Hbv antigen formulation for treating hepatitis b
|
|
WO2025172435A1
(en)
|
2024-02-13 |
2025-08-21 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Hbv antigen formulation for treating hepatitis b
|